Showing results (161-170 of 248) with videos related to

Sort By:
Pageof 25
Cancers|July 2, 2021
Genetic Characterization and Clinical Features of Helicobacter pylori Negative Gastric Mucosa-Associated Lymphoid Tissue LymphomaBarbara Kiesewetter, Christiane Copie-Bergman, Michael Levy, et al.
Journal of Geriatric Oncology|July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana LinfomiFrancesco Merli, Federica Cavallo, Flavia Salvi, et al.
Diagnostics (Basel, Switzerland)|April 30, 2021
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine ImplementationMartina Ferrante, Daniela Furlan, Silvia Zibellini, et al.
The New England Journal of Medicine|August 31, 2012
MYD88 L265P somatic mutation in Waldenström's macroglobulinemiaSteven P Treon, Lian Xu, Guang Yang, et al.
Hematological Oncology|February 7, 2019
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical networkSara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2017
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular LymphomaStefano Luminari, Angela Ferrari, Martina Manni, et al.
American Journal of Hematology|October 24, 2025
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast NephropathyHeinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, et al.
Hematological Oncology|June 2, 2024
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosisClaudia Bellofiore, Pietro Benvenuti, Roberto Mina, et al.
British Journal of Haematology|December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE studyFederico Stella, Annalisa Chiappella, Martina Magni, et al.
The Lancet. Oncology|February 23, 2016
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trialMarek Trněný, Thierry Lamy, Jan Walewski, et al.
Pageof 25